• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,207.24 -2,496.89
( -3.26%)
Global Indices
Nasdaq
46,241.86 -772.41
(-1.64%)
Dow Jones
6,644.85 -92.24
(-1.37%)
Hang Seng
53,297.18 -1,942.22
(-3.52%)
Nikkei 225
10,057.93 -247.36
(-2.40%)
Forex
USD-INR
92.39 0.06
(0.06%)
EUR-INR
106.38 0.46
(0.44%)
GBP-INR
123.15 0.52
(0.42%)
JPY-INR
0.58 0.00
(0.14%)

EQUITY - MARKET SCREENER

Vilin Bio Med Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
78871
INE0L4V01013
16.5329749
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VILINBIO
219.06
48.89
EPS(TTM)
Face Value()
Div & Yield %
0.16
10
0
 

Apollo Tyres slides after Q2 PAT slumps 13% YoY to Rs 258 cr
Nov 14,2025

EBITDA in Q2 FY26 jumped 16.3% to Rs 1,020.7 crore as compared to Rs 877.9 crore reported in Q2 FY25. EBITDA margin improved to 14.9% during the quarter as against 13.6% in the same quarter previous year

The company reported profit before exceptional items and tax of Rs 566.12 crore in Q2 FY26, compared to Rs 404.09 crore recorded in the same period a year ago. The firm reported exceptional items of Rs 180.04 crore during the quarter.

On the segmental front, the company’s revenue from the Asia Pacific, Middle East, and Africa (APMEA) segment stood at Rs 4,822.78 crore (up 5.62% YoY), income from Europe was Rs 2,190.56 crore (up 13.58% YoY), while revenue from other regions stood at Rs 1,178.01 crore (down 30.73% YoY) during the period under review.

On a half-year basis, the company’s net profit tumbled 54.85% to Rs 270.93 crore on a 4.85% rise in revenue from operations to Rs 13,391.85 crore in H1 FY26 over H1 FY25.

Meanwhile, the company’s board has also approved a plan to raise Rs 1,000 crores through the issue of Non-Convertible Debentures (NCDs). These NCDs will be allotted through a private placement exercise.

Apollo Tyres' principal business activity is the manufacturing and sale of automotive tires.